Thursday, April 23, 2020 9:39:36 AM
In the United States, DetermaRx™ has rapidly gained traction, expanding to 18 sites in the first three months since commercial launch
IRVINE, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has entered a distribution agreement with CORE Diagnostics, expanding the commercial availability of DetermaRx™ to India, the Middle East and Africa. DetermaRx™ is Oncocyte’s treatment stratification test that identifies patients at high risk for lung cancer recurrence, who may benefit from adjuvant chemotherapy post-surgery.
CORE Diagnostics is one of the fastest-growing clinical laboratories in India, focused on bringing the most advanced testing techniques and expertise to the country. Under the terms of the agreement, tissue samples needed for the test will be run in the United States by Oncocyte, while CORE Diagnostics will generate test orders and provide customer service to patients.
“As we think about expanding beyond the U.S., one of our strategies is to partner with labs focused on delivering high value, proprietary diagnostics into an existing oncology channel to generate demand and brand awareness. CORE Diagnostics does exactly that,” said Ron Andrews, Chief Executive Officer of Oncocyte. “We believe CORE’s oncology salesforce of 100 people and customer base of 5000 ordering physicians in 12 different countries will be critical as we work to increase awareness and availability of our tests among physicians and patients globally. We are thrilled to embark on this collaboration with such a respected and growing brand in this important market and are looking forward to tens of thousands more patients having access to our tests, potentially saving lives in the process. As we continue to grow, we intend to extend this distribution model to other geographies including South America and other parts of Asia as well.”
Zoya Brar, Chief Executive Officer and Founder of CORE Diagnostics added, “The market for molecular testing in India and the Middle East is quite large. We focus on partnering with labs that offer proprietary diagnostics fulfilling an unmet need at a patient friendly price for our population, and we believe DetermaRx perfectly fits these characteristics. We look forward to making this test and potentially other diagnostic tests from Oncocyte available across these countries in the future.”
DetermaRx was launched in the United States through an Early Access Program (EAP) in late January 2020 with two sites. Since then it has continued to gain traction, rapidly expanding to eighteen sites in just the first three months of launch. These targeted sites are located across the country including multiple community cancer centers where early stage cancer is managed including physicians from large community-based systems, such as Dignity Health and Northshore Oncology. The Company has onboarded eight sites in the past month despite COVID-19 challenges throughout the country. Oncocyte will begin serving physicians in these sites once surgeries for early stage lung cancer ramp back up over the coming months.
“We’re thrilled with the progress made thus far to expand the availability of DetermaRx, both in the U.S. and beyond,” said Padma Sundar, Senior Vice President, Marketing and Market Access at Oncocyte. “I’m incredibly proud of our team’s rapid pivot to virtual operations as the COVID-19 situation began to progress and am confident that the quick expansion in DetermaRx test adoption sites was driven by this foresight. Our online peer-to-peer physician engagement initiatives have reached over 1500 participants. Additionally, we’ve seen success with virtual onboarding of sites using sophisticated physician office-friendly software for easy test ordering, processing and delivery of test reports, as well as prompt customer service. We intend to take these same steps to ensure similar expansion outside of the U.S. and are looking forward to continued progress.”
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. DetermaDx™, the company’s liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify if a patients’ lung nodules are benign, which may enable them to avoid potentially risky invasive diagnostic procedures. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.
DetermaDx, DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.
Recent OCX News
- PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology • GlobeNewswire Inc. • 08/20/2024 01:00:00 PM
- Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study • GlobeNewswire Inc. • 08/12/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 10:37:23 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 10:25:21 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/09/2024 04:15:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:27:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:10:22 PM
- Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Oncocyte Announces August Investor Conferences Participation • GlobeNewswire Inc. • 08/05/2024 08:05:00 PM
- Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:05:21 PM
- MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode • GlobeNewswire Inc. • 07/11/2024 12:00:00 PM
- Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move • GlobeNewswire Inc. • 06/24/2024 04:41:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:10:27 PM
- Oncocyte Appoints Andrea James as Chief Financial Officer • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/04/2024 09:02:47 PM
- Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study • GlobeNewswire Inc. • 06/03/2024 06:13:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:31 PM
- Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine • GlobeNewswire Inc. • 05/30/2024 08:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:24 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/23/2024 03:26:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 09:18:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:56:24 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/17/2024 09:11:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM